[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Identifieur interne : 000077 ( Main/Exploration ); précédent : 000076; suivant : 000078[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
Auteurs :Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-inflammatoires non stéroïdiens (administration et posologie), Calendrier d'administration des médicaments, Chine, Chloroquine (administration et posologie), Chloroquine (analogues et dérivés), Consensus, Durée du séjour, Guides de bonnes pratiques cliniques comme sujet, Humains, Infections à coronavirus (), Pneumopathie virale (), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (étiologie).
- MESH :
- administration et posologie : Anti-inflammatoires non stéroïdiens, Chloroquine.
- analogues et dérivés : Chloroquine.
- traitement médicamenteux : Pneumopathie virale.
- étiologie : Pneumopathie virale.
- Calendrier d'administration des médicaments, Chine, Consensus, Durée du séjour, Guides de bonnes pratiques cliniques comme sujet, Humains, Infections à coronavirus, Pneumopathie virale.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), China, Chloroquine (administration & dosage), Chloroquine (analogs & derivatives), Consensus, Coronavirus Infections (complications), Drug Administration Schedule, Humans, Length of Stay, Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (etiology), Practice Guidelines as Topic.
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Non-Steroidal, Chloroquine.
- chemical , analogs & derivatives : Chloroquine.
- geographic : China.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Pneumonia, Viral.
- etiology : Pneumonia, Viral.
- Consensus, Drug Administration Schedule, Humans, Length of Stay, Practice Guidelines as Topic.
Abstract
At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.
DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009
PubMed: 32164085
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000595
- to stream PubMed, to step Curation: 000595
- to stream PubMed, to step Checkpoint: 000072
- to stream Ncbi, to step Merge: 000F96
- to stream Ncbi, to step Curation: 000F96
- to stream Ncbi, to step Checkpoint: 000F96
- to stream Main, to step Merge: 000079
- to stream Main, to step Curation: 000077
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32164085</idno><idno type="pmid">32164085</idno><idno type="doi">10.3760/cma.j.issn.1001-0939.2020.03.009</idno><idno type="wicri:Area/PubMed/Corpus">000595</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000595</idno><idno type="wicri:Area/PubMed/Curation">000595</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000595</idno><idno type="wicri:Area/PubMed/Checkpoint">000072</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000072</idno><idno type="wicri:Area/Ncbi/Merge">000F96</idno><idno type="wicri:Area/Ncbi/Curation">000F96</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F96</idno><idno type="wicri:Area/Main/Merge">000079</idno><idno type="wicri:Area/Main/Curation">000077</idno><idno type="wicri:Area/Main/Exploration">000077</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].</title></analytic><series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title><idno type="ISSN">1001-0939</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term><term>China</term><term>Chloroquine (administration & dosage)</term><term>Chloroquine (analogs & derivatives)</term><term>Consensus</term><term>Coronavirus Infections (complications)</term><term>Drug Administration Schedule</term><term>Humans</term><term>Length of Stay</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (etiology)</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens (administration et posologie)</term><term>Calendrier d'administration des médicaments</term><term>Chine</term><term>Chloroquine (administration et posologie)</term><term>Chloroquine (analogues et dérivés)</term><term>Consensus</term><term>Durée du séjour</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Chloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Chloroquine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens</term><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Consensus</term><term>Drug Administration Schedule</term><term>Humans</term><term>Length of Stay</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Calendrier d'administration des médicaments</term><term>Chine</term><term>Consensus</term><term>Durée du séjour</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000077 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000077 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32164085
|texte= [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32164085" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |